Multiomics is becoming a clinical reality
According to the latest research (2025–2026) on multiomics analysis, this technique is providing tangible results for precision medicine. Here's some key information on the progress that's being reported:
GREAT NEWS! — MORE RELIABLE PREDICTIONS FOR DISEASES: Recent studies have shown that, compared with clinical data alone, the integration of genomics, transcriptomics, proteomics, metabolomics, and epigenomics provides better prediction for the onset of diseases.
EVEN BETTER, PATIENT DIVERSIFICATION IS IMPROVING: Multiomics improves the ability to recognize patients that are most likely to benefit from a given treatment, especially oncology and immunotherapy.
AI IS THE FUTURE! Artificial intelligence, graph-based learning and network-based models are becoming the key methods for multiomics data integration and for the identification of novel biomarkers, disease subtypes, and therapeutic targets.
MULTIOMICS IS MAKING IT EASIER FOR CANCER RESEARCH: Cancer research is aided by the ability to study individual cells in their native (!) tissue locations.
GOOD NEWS: MULTIOMICS IS EASIER TO ACCESS: Multiomics is transforming the ability to study individual cells in their native tissue locations, which provides greater insights into the heterogeneity of tumors, the progression of disease, and treatment resistance. Many research facilities are adopting automated workflows, making this research easier to access.
Some clinical results
- Predicting which patients are likely to develop invasive lung cancer (and potentially avoiding unnecessary biopsy procedures).
- Predicting which patients are likely to develop diabetes and cardiovascular diseases.
- Predicting which patients are likely to benefit from immunotherapy for liver cancer.
- Predicting which patients with rare disorders are most likely to benefit from novel integrated genomic and transcriptomic sequencing.
What's next?
Hurdles still exist for multiomics to occur routinely in clinics, including:
- Integration of data at different molecular levels
- Incomplete datasets
- Problems with reproducibility and consistency
- Validation in large clinical cohorts
- Costs and practicality
Although clear problems and barriers exist, we are highly optimistic. We are confident the next best thing in history won't be just gathering and analyzing data like never before — it will be AI. Precision medicine will move beyond relying on an individual's DNA and will depend upon multiple biological layers for accurate diagnosis, more effective therapeutic options, and tailored care.
Multiomics is in its final frontier of testing. Systems and services will focus on improving this cornerstone of research faster and more efficiently than anything we have ever seen.